Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin.

We formerly reported that the combination of dichloroacetate, omeprazole, and tamoxifen blocked cancer progression by reducing lactic acid production and inducing superoxide production. Recently, ivermectin, a well-known anti-parasite drug, was reported to share the same mechanisms with them and have anti-tumor activity. Here, we present three patients in whom the combination of dichloroacetate, omeprazole (plus tamoxifen), and ivermectin dramatically relieved the symptoms accompanying cancer and sarcoma progression.

Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors.

It has been reported that treating cancer cells with dichloroacetate (DCA), an approved treatment for congenital lactic acidosis, reverses the Warburg effect and inhibits tumor growth). Furthermore, omeprazole (OMP) is a well-known agent that enhances the effects of anticancer drugs. The aim of this study was to find clinically-used drugs that enhance the effects of DCA.

Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report.

Background/aims: Omeprazole (OPZ) and tamoxifen (TAM) strengthen the effects of anticancer drugs and dichloroacetate (DCA) inhibits tumor growth. This study assesses the synergistic effects of these drugs.

Methodology: HT1080 human fibrosarcoma cells and WI-38 human fibroblasts were used as test and control cells, respectively.

The formulated growth of early gastric cancer.

Although the proportion of early gastric cancer is rising in the incidence of gastric cancer as a whole, its natural history is still under discussion. We report a patient who was diagnosed with early gastric cancer and who had undergone barium studies once a year for the three previous years. The exact, increasing size of the tumor could be measured at these four time points, and the data show, almost exactly, the line calculated by the formula S = 0.

Midazolam sedation for upper gastrointestinal endoscopy: comparison between the states of patients in partial and complete amnesia.

Background/aims: The amnesia produced by anesthesia is advantageous for unpleasant procedures like gastroscopy, and midazolam is one of the most commonly used anesthesias for endoscopy. However the proper use of midazolam from the viewpoint of complete amnesia has been discussed very little.

Methodology: One hundred and thirty-three unselected patients about to undergo upper gastrointestinal endoscopy were premedicated with sufficient intravenous midazolam to cause enough sedation so that no response was evoked when calling their name.